Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ME003
- Development stage
- Preclinical
- Lead developer
- Letolab
- Modality
- Peptides
01
Overview
ME003 is a peptide-based agonist of the fibroblast growth factor 21 (FGF21) pathway, currently under development by Letolab for the treatment of non-alcoholic steatohepatitis (NASH). FGF21 is a metabolic hormone that plays a critical role in regulating glucose and lipid metabolism; its activation is associated with reduced hepatic fat accumulation (steatosis), improved insulin sensitivity, and decreased liver inflammation and fibrosis. ME003 is designed as a therapeutic peptide to mimic or enhance FGF21 signaling to address the underlying metabolic dysregulation in NASH. The program is currently in the IND-enabling phase of development.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on ME003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ME003.